Drug Profile
Diquafosol - Merck/Santen Pharmaceutical
Alternative Names: DE-089; DE-089C; Diquafosol sodium; Diquafosol tetrasodium; Diquas; Diquas ophthalmic solution; INS 365; KPY 998; Prolacria; STN-1008903Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Inspire Pharmaceuticals
- Developer Inspire Pharmaceuticals; Meiji Seika Pharma; Santen Pharmaceutical
- Class Antibronchitics; Antifibrotics; Expectorants; Eye disorder therapies; Polyphosphates; Small molecules; Uracil nucleotides
- Mechanism of Action Purinoceptor P2U agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dry eyes
- Discontinued Bronchitis; Chronic obstructive pulmonary disease; Corneal ulcer; Cystic fibrosis
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Dry-eyes in Taiwan (Ophthalmic, Liquid)
- 28 Aug 2020 Santen Pharmaceutical initiates a phase IIIb trial in Dry eyes in Japan (JapicCTI205466)
- 08 May 2020 Allergan has been acquired and merged into AbbVie